Fortamet
Diabetic Ketoacidosis, Congestive Heart Failure, Type 1 Diabetes + 16 more
Treatment
22 FDA approvals
20 Active Studies for Fortamet
Treatment for
Diabetic Ketoacidosis
What is Fortamet
Metformin
The Generic name of this drug
Treatment Summary
Metformin is a medication used to treat type 2 diabetes. It is the most commonly prescribed drug for this condition and has been prescribed to over 120 million people around the world. Metformin works by reducing blood sugar levels without causing low blood sugar, and it also helps to reduce insulin resistance and insulin levels. Additionally, metformin can lead to weight loss in obese type 2 diabetes patients. It was first approved for use in Canada in 1972 and in the US in 1995, and it is available in regular and extended-release forms.
Metformin Hydrochloride
is the brand name
Fortamet Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metformin Hydrochloride
Metformin
2002
1263
Approved as Treatment by the FDA
Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 22 uses which include Heart Failure and Type 2 Diabetes Mellitus .
Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Chronic Kidney Disease
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Renal Insufficiency
Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin
Ejection fraction decreased
Used to treat Ejection fraction decreased in combination with Dapagliflozin
Heart Failure
Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin
Kidney Failure
Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin
Ketosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Diet
Used to treat Diet in combination with Dapagliflozin
Hospitalizations
Used to treat Hospitalizations in combination with Dapagliflozin
Congestive Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Physical Activity
Used to treat Exercise in combination with Dapagliflozin
Chronic Kidney Disease (CKD)
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Type 1 Diabetes Mellitus
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Diabetic Ketoacidosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Dapagliflozin
Diabetes Mellitus
Used to treat uncontrolled diabetes in combination with Rosiglitazone
Cardiovascular Disease
Used to treat Cardiovascular Risk in combination with Dapagliflozin
Cardiovascular Diseases
Used to treat established cardiovascular disease in combination with Dapagliflozin
Heart failure
Used to treat Heart Failure in combination with Dapagliflozin
Type 1 Diabetes
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Effectiveness
How Fortamet Affects Patients
Insulin is a hormone that helps keep your blood sugar levels in check. People with type 2 diabetes don't respond as well to insulin, causing their blood sugar levels to become too high. Metformin counteracts this by reducing the amount of sugar made by the liver and stopping sugar from being absorbed by the intestines. It also helps the body use insulin more effectively. In a clinical trial, people taking metformin saw their fasting plasma glucose levels decrease by an average of 59mg/dL, while those taking a placebo saw an average increase of 6.3mg/dL. The Glycosylated hemoglobin (Hb
How Fortamet works in the body
Metformin works differently than other diabetes medications. It lowers blood glucose levels by reducing how much glucose is made in the liver, stopping glucose from being absorbed in the intestines, and increasing the body’s sensitivity to insulin. It does this by entering cells and mitochondria and inhibiting the production of mitochondrial ATP, leading to an increase in AMP:ATP ratios. This activates AMPK, an enzyme that helps regulate glucose metabolism, and stops fructose-1,6-bisphosphatase from producing glucose, which helps reduce gluconeogenesis. It also decreases the production of cAMP, a derivative of ATP.
When to interrupt dosage
The prescribed dosage of Fortamet is contingent upon the identified illness, such as Diet, inadequate reaction to metformin and Diabetic Ketoacidosis. The measure of dosage is based on the system of delivery (e.g. Oral or Tablet - Oral) specified in the table beneath.
Condition
Dosage
Administration
Cardiovascular Diseases
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
inadequate response to metformin
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Insulin Resistance
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Renal Insufficiency
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diabetes Mellitus
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Congestive Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Type 2 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Chronic Kidney Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diabetic Ketoacidosis
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Physical Activity
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Kidney Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diet
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Hospitalizations
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Type 1 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Polycystic Ovarian Syndrome
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Mortality
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Ejection fraction decreased
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Warnings
Fortamet Contraindications
Condition
Risk Level
Notes
Liver Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
Heart Arrest
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Operative Surgery
Do Not Combine
Metabolic acidosis
Do Not Combine
Heart Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
kidney function unknown
Do Not Combine
Hypovolemic Shock
Do Not Combine
serum creatinine above upper limit for age range
Do Not Combine
ethanol
Do Not Combine
Acute Coryza
Do Not Combine
Hypoxemia
Do Not Combine
Liver Failure
Do Not Combine
Acidosis, Lactic
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Renal Insufficiency
Do Not Combine
Renal Insufficiency, Chronic
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Metformin may interact with Pulse Frequency
There are 20 known major drug interactions with Fortamet.
Common Fortamet Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Metformin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Metformin.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Metformin.
Abacavir
Minor
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Fortamet Toxicity & Overdose Risk
Metformin has an oral LD50 in rats of 1g/kg, an intraperitoneal LD50 of 500mg/kg in rats, and a subcutaneous LD50 of 300mg/kg in rats. The oral LD50 in mice is 1450mg/kg, the intraperitoneal LD50 is 420mg/kg, and the subcutaneous LD50 is 225mg/kg. Those taking metformin may be at risk for lactic acidosis, which is characterized by high blood lactate levels, anion gap acidosis, and increased lactate:pyruvate ratio. Risk
Fortamet Novel Uses: Which Conditions Have a Clinical Trial Featuring Fortamet?
Currently, there are 346 active clinical trials assessing the potential of Fortamet to provide a remedy for Type 2 Diabetes, Type 1 Diabetes and inadequate responses to metformin.
Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease
96 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Cardiovascular Diseases
0 Actively Recruiting
Congestive Heart Failure
177 Actively Recruiting
Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 4, Phase 3
Type 1 Diabetes
191 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Cardiovascular Disease
25 Actively Recruiting
Not Applicable, Early Phase 1, Phase 3, Phase 2
Type 2 Diabetes
160 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Kidney Failure
38 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Physical Activity
23 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Insulin Resistance
0 Actively Recruiting
Renal Insufficiency
0 Actively Recruiting
Cardiovascular Mortality
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Hospitalizations
1 Actively Recruiting
Not Applicable
Diabetic Ketoacidosis
2 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Polycystic Ovarian Syndrome
7 Actively Recruiting
Not Applicable, Phase 1
inadequate response to metformin
0 Actively Recruiting
Heart Failure
0 Actively Recruiting
Diet
4 Actively Recruiting
Not Applicable, Phase 1
Diabetes Mellitus
0 Actively Recruiting
Fortamet Reviews: What are patients saying about Fortamet?
5
Patient Review
11/22/2008
Fortamet for Type 2 Diabetes Mellitus
5
Patient Review
9/23/2009
Fortamet for Type 2 Diabetes Mellitus
5
Patient Review
2/27/2011
Fortamet for Type 2 Diabetes Mellitus
5
Patient Review
11/12/2010
Fortamet for Type 2 Diabetes Mellitus
4.7
Patient Review
5/11/2009
Fortamet for Disease of Ovaries with Cysts
4.7
Patient Review
10/2/2010
Fortamet for Disease of Ovaries with Cysts
4.3
Patient Review
7/3/2011
Fortamet for Type 2 Diabetes Mellitus
4
Patient Review
7/7/2009
Fortamet for Disease of Ovaries with Cysts
4
Patient Review
3/2/2010
Fortamet for Type 2 Diabetes Mellitus
4
Patient Review
7/27/2010
Fortamet for Type 2 Diabetes Mellitus
4
Patient Review
4/2/2009
Fortamet for Type 2 Diabetes Mellitus
4
Patient Review
3/12/2010
Fortamet for Type 2 Diabetes Mellitus
3.7
Patient Review
7/22/2009
Fortamet for Type 2 Diabetes Mellitus
2.7
Patient Review
8/4/2010
Fortamet for Type 2 Diabetes Mellitus
2.3
Patient Review
3/8/2009
Fortamet for Type 2 Diabetes Mellitus
1
Patient Review
11/14/2008
Fortamet for Type 2 Diabetes Mellitus
1
Patient Review
1/4/2010
Fortamet for Type 2 Diabetes Mellitus
Patient Q&A Section about fortamet
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is Fortamet used for?
"Metformin is a medication used to control high blood sugar. It is often used in combination with diet and exercise to control blood sugar in patients with type 2 diabetes. Controlling high blood sugar helps prevent a variety of issues including kidney damage, blindness, nerve problems, and loss of limbs."
Answered by AI
Is metformin er the same as Fortamet?
"There are a few different ER products for metformin, including Glumetza and Fortamet. They work differently by slowly releasing metformin over time. Since they don't work in the same way, Glumetza and Fortamet can't be used interchangeably."
Answered by AI
What kind of drug is Fortamet?
"Fortamet is a diabetes medication taken orally by people with type 2 diabetes. It is sometimes used in combination with insulin or other medications, but not for those with type 1 diabetes. Fortamet is available in generic form."
Answered by AI
What is the generic for Fortamet?
"Mylan has introduced metformin hydrochloride expanded-discharge tablets, the nonexclusive adaptation of Watson's Fortamet, in 500 mg and 1000 mg portions. This nonexclusive item is implied for use as an embellishment to eating routine and activity to improve glycemic control in grown-ups with type 2 diabetes mellitus."
Answered by AI